Prenatal diagnosis of congenital adrenal hyperplasia owing to 21-hydroxylase deficiency

Mabel Yau, Christian Pina, Ahmed Khattab, Ariella Barhen, Maria I. New

Research output: Contribution to journalReview articlepeer-review

Abstract

A non-invasive prenatal diagnostic method has been developed for congenital adrenal hyperplasia (CAH) owing to 21-hydroxylase deficiency. Excess fetal androgen production causes genital virilization in female fetuses affected with classical forms of CAH. In order to prevent genital ambiguity, prenatal dexamethasone treatment must be administered before the 9th week of gestation when genital organogenesis occurs. Invasive prenatal diagnostic methods do not yield a genetic diagnosis until after genital organogenesis begins. This new methodology could allow for the targeted treatment of affected female fetuses and avoid unnecessary prenatal treatment of males or unaffected females.

Original languageEnglish
Pages (from-to)487-490
Number of pages4
JournalExpert Opinion on Orphan Drugs
Volume3
Issue number5
DOIs
StatePublished - 1 May 2015

Keywords

  • 21-hydroxylase congenital adrenal hyperplasia
  • Congenital adrenal hyperplasia
  • Dexamethasone treatment
  • Prenatal diagnosis

Fingerprint

Dive into the research topics of 'Prenatal diagnosis of congenital adrenal hyperplasia owing to 21-hydroxylase deficiency'. Together they form a unique fingerprint.

Cite this